LaFleur & Godfrey LLC Raises Stock Holdings in Kenvue Inc. (NYSE:KVUE)

LaFleur & Godfrey LLC boosted its position in Kenvue Inc. (NYSE:KVUE) by 12.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 62,650 shares of the company’s stock after purchasing an additional 6,985 shares during the quarter. LaFleur & Godfrey LLC’s holdings in Kenvue were worth $1,449,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Cornerstone Wealth Group LLC lifted its stake in shares of Kenvue by 176.2% during the first quarter. Cornerstone Wealth Group LLC now owns 350,371 shares of the company’s stock valued at $7,519,000 after buying an additional 223,537 shares during the period. NBC Securities Inc. boosted its holdings in shares of Kenvue by 8.4% during the first quarter. NBC Securities Inc. now owns 11,301 shares of the company’s stock worth $242,000 after purchasing an additional 879 shares during the last quarter. Janney Montgomery Scott LLC grew its position in shares of Kenvue by 56.2% in the first quarter. Janney Montgomery Scott LLC now owns 1,840,875 shares of the company’s stock valued at $39,505,000 after purchasing an additional 662,666 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Kenvue during the first quarter worth about $1,050,000. Finally, Norden Group LLC acquired a new stake in Kenvue in the 1st quarter worth about $1,792,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 0.5 %

Shares of KVUE stock traded down $0.10 on Wednesday, hitting $21.66. The stock had a trading volume of 3,187,793 shares, compared to its average volume of 18,133,279. The stock’s 50 day moving average is $22.22 and its 200-day moving average is $20.18. The firm has a market capitalization of $41.47 billion, a price-to-earnings ratio of 27.90, a P/E/G ratio of 2.76 and a beta of 1.40. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $23.55. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period last year, the firm earned $0.32 earnings per share. The company’s revenue was down .3% on a year-over-year basis. As a group, research analysts expect that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.79%. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue’s dividend payout ratio is presently 105.13%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on KVUE shares. Jefferies Financial Group started coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. Deutsche Bank Aktiengesellschaft upped their price objective on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Citigroup reduced their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. UBS Group increased their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $22.20.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.